<DOC>
	<DOCNO>NCT00295711</DOCNO>
	<brief_summary>The primary objective placebo-controlled clinical trial evaluate analgesic efficacy safety bicifadine three oral dose level compare placebo patient moderate severe chronic low back pain . The secondary objective investigate dose-response relationship three dose level bicifadine , evaluate clinical meaningfulness bicifadine efficacy , evaluate effect bicifadine function general quality life , describe population pharmacokinetics bicifadine patient chronic low back pain , evaluate safety follow discontinuation bicifadine treatment .</brief_summary>
	<brief_title>Efficacy Safety Bicifadine Treatment Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Main Patients low back pain assess Class 1 , Class 2 Class 3 accord Quebec Task Force Classification Spinal Disorders without detectable leg weakness neurological examination . Patients must require average daily analgesic treatment low back pain least 3 month prior dose . Main Patients may moderate severe pain location low back ( exception radiation low extremity ) . Patients must lower back surgery within 6 month prior baseline , epidural corticosteroid injection within 3 month prior baseline . Patients may unstable medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>bicifadine</keyword>
	<keyword>chronic low back pain</keyword>
</DOC>